Rani Therapeutics Holdings vs Entrada Therapeutics
Entrada Therapeutics is the larger business, with $25.4m of revenue in fiscal 2025 against $1.6m for Rani Therapeutics Holdings (15.6 times as much). Rani Therapeutics Holdings grew faster (58.9% against -87.9%). Entrada Therapeutics kept more of each dollar of sales as profit: a net margin of -565.5% against -1817.1%. Rani Therapeutics Holdings carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Rani Therapeutics HoldingsRANI, 2025 | Entrada TherapeuticsTRDA, 2025 |
|---|---|---|
| Revenue | $1.6m | $25.4m |
| Revenue growth | 58.9% | -87.9% |
| Net income | −$29.7m | −$144m |
| Operating margin | -2346.0% | -621.1% |
| Net margin | -1817.1% | -565.5% |
| Return on equity | -169.6% | -39.1% |
| Free cash flow | −$18.8m | −$130m |
| Cash | $18.6m | $90.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 69 | 152 |
| Market value | $104m | $185m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 2 buys, 1 sales | 17 buys, 44 sales |